Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies
Elisabetta Fratta, Barbara Montico, Aurora Rizzo, Francesca Colizzi, Luca Sigalotti, Riccardo Dolcetti
Oncotarget | IMPACT JOURNALS LLC | Published : 2016
In recent years, recurrent somatic mutations in epigenetic regulators have been identified in patients with hematological malignancies. Furthermore, chromosomal translocations in which the fusion protein partners are themselves epigenetic regulators or where epigenetic regulators are recruited/targeted by oncogenic fusion proteins have also been described. Evidence has accumulated showing that "epigenetic drugs" are likely to provide clinical benefits in several hematological malignancies, granting their approval for the treatment of myelodysplastic syndromes and cutaneous T-cell lymphomas. A large number of pre-clinical and clinical trials evaluating epigenetic drugs alone or in combination..View full abstract
Awarded by Associazione Italiana per la Ricerca sul Cancro
The authors thank Mrs. Anna Vallerugo, M.A., for her writing assistance. This study was supported by grants from the Associazione Italiana per la Ricerca sul Cancro (contract 14287 to RD) and from the Centro di Riferimento Oncologico I.R.C.C.S. (Intramural grant to EF and LS).